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Pharmacokinetics and haemodynamic effects of the 
angiotensin converting enzyme inhibitor cilazapril 
in hypertensive patients with normal and 
impaired renal function
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M. HUYSMANS
of Medicine
1 Department of Pharmacokinetics, Roche, Basle, Switzerland
1 The pharmacokinetic and pharmacodynamic properties of the angiotensin 
converting enzyme (ACE) inhibitor cilazapril were studied in 30 hypertensive 
patients with various degrees of renal function.
2 After a single oral dose, apparent cilazaprilat clearance was dependent on
renal function being 16.0 + 3.0, 11.1 + 3.0, 8.7 +3.7 and 6.7 + l l l h ”1 
(means+ s.d.) in patients with creatinine clearances (CLcr) of >100, 41-100, 
21-40, and 8-20 ml min“1, respectively.
3 During 11 weeks of treatment with cilazapril, doses were adjusted to the CLcr 
and varied from 0.5 to 5.0 mg once daily. At 24 h after drug administration a 
clear antihypertensive response was seen only in the low clearance groups 
(CLcr< 40m l min-1). In contrast, and despite higher once daily dosages, the 
decline of mean arterial pressure was small and cilazaprilat concentrations 
after 24 h were lower in the high clearance groups.
4 This study demonstrates that chronic once daily treatment with cilazapril is 
effective in patients with impaired renal function at dosages adjusted to 
creatinine clearance. No accumulation was seen. Since cilazaprilat clearance 
was high in the high creatinine clearance groups, a clear antihypertensive 
response in these groups was only seen at 3 h after drug administration.
Keywords cilazapril renal failure hypertension pharmacokinetics proteinuria
The ACE inhibitor cilazapril is hydrolysed predomi­
nantly in the liver and blood to its active form 
cilazaprilat. This metabolite is excreted mainly by the 
kidneys [1]. In patients with normal renal function 
most of the unbound cilazaprilat is rapidly excreted 
in the first 8 h after drug administration. However, 
probably due to the high affinity of cilazaprilat for 
angiotensin converting enzyme the terminal half-life of 
this drug is as long as 40 to 50 h [1, 2]. In patients
with renal insufficiency only limited pharmacokinetic 
and pharmacodynamic data on chronic cilazaprilat 
administration are available [3-5]. Therefore, we 
investigated the pharmacokinetic properties of cilazapri­
lat in hypertensive patients with various degrees of renal
insufficiency both after a single dose as well as during 
chronic treatment. The antihypertensive and antipro- 
teinuric effects of various dosages of cilazapril as well 
as their relation to creatinine clearance (CLor) and 
angiotensin converting enzyme (ACE) inhibition were 
studied at different times after drug administration.
Methods
Thirty hypertensive patients without other serious 
cardiovascular disorders and with various but stable 
levels of renal function were selected. At least 3 weeks 
before the start of the study all antihypertensive agents 
and any other drug possibly interfering with blood
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pressure regulation or renal function were discontinued. and ACE activity were performed by radioenzymatic 
Patients were divided in four groups: creatinine clearance methods [1]. During chronic treatment these were
(CLcr)>  100 ml m in“ 1 (group A), CLcr 41-100 ml min"
1 (group C) and CL(group B), CLcr 21-40 ml min
1 measured at all visits at 24 h after drug administration
r and additionally at week 2 and 4 at 3 h after drug
8-20 ml min ~1 (group D). After three baseline measure- administration. At each visit serum potassium and
ments of haemodynamic and laboratory parameters on creatinine were measured. Other routine blood evalu-
separate days performed at the same time in the morning, ations remained stable throughout the study. At baseline
patients received a single (either 0.5 or 1.0 mg) oral dose plasma renin activity (PRA) was determined by radio-
of cilazapril. During the subsequent 4 days, haemo- immunoassay [6]. In 24 h urine samples, concentrations
dynamic and laboratory parameters were assessed at of creatinine, sodium, potassium, and protein were
regular intervals. Thereafter, patients were treated during measured at baseline and during chronic treatment.
11 weeks with a single daily dose of cilazapril (see below). Patients were ad vised to adhere to a constant intake of
Control visits were performed at weekly intervals during sodium (150 mmol day” 1) and potassium (60-70 mmol 
the first 4 weeks and further at week 7 and 11. day 1 ) which was confirmed by urinary excretion.
The study protocol was approved by the Ethical 
Committee of the University Hospital in Nijmegen. All 
patients gave their written informed consent.
For analysis, only relative changes of mean arterial 
Blood pressure measurements pressure (MAP) compared with baseline were used. In
one patient of group D the study was discontinued at 
At baseline standard sphygmomanometer supine dias- week 3 because of peritonitis. In this patient only results
tolic blood pressure (BP) was greater than 90mmHg. of the single dose part were used for analysis. For
All other BP and heart rate (HR) measurements were determination of cilazaprilat pharmacokinetics individ- 
done by automatic devices (DINAMAP, Criticon Inc., ual data were analyzed by non-compartmental methods 
Tampa, Florida or BOSCH EBM502, Bosch GMBH, [7 ]. Cilazaprilat peak concentrations (Cmax) and time
Berlin, Germany). After 5 min supine rest, BP was to peak (imax) were directly observed from analytical
measured at 1 min intervals for 3 min in supine position results. Since the decline of the logarithm of cilazaprilat
using the same arm throughout the study. During concentrations is essentially non-linear and may vary
chronic treatment, BP and HR were always measured widely [2, 8], calculation of the area under the curve
'  • /  « /  U  ’  J l  1
24 h after drug administration at the same time in the 
morning, with additional measurements 3 h after drug
to infinity may be unreliable. Therefore, the 
after the first dose was also calculated by the
administration at weeks 2 and 4. The dose of cilazapril trapezoidal method to 24 h (AUC(0, 24 h)). Since
was increased after 2 weeks of treatment (see below) if dosages of cilazapril were different in the high (AB) and
diastolic blood pressure reduction 24 h after drug low clearance groups (CD), AUC (0, 24 h) and C
administration was less than 10% or if diastolic blood were normalized to a dose of 1 mg for comparison of
pressure remained higher than 90 mml-Ig. Thus the the results in the respective clearance groups. Apparent
max
cilazapril dose was increased in seven, five, four and 
four patients of group A, B, C, and D, ref 
Since patient numbers were small, data were analyzed
oral clearance (CL0) was calculated as dose/AUC(0, 
24 h).
Analysis of the pharmacokinetic data from the single
for the combined high and low clearance groups AB dose part of the
and CD, respectively. Pharmacokinetic
11 by ANOVA.
haemodynamic data from
Drug dosage
multiple dose part (Table 3) were analyzed by distri­
bution-free repeated measures analysis [9]. All other 
comparisons were assessed by Wilcoxon’s rank sum test
and Wilcoxon’s signed Correlations were
In the single dose part of the study patients of groups A assessed by determining the correlation coefficient 
and B received 1.0 mg cilazapril orally, whereas those according to Spearman or where appropriate according 
of groups C and D received 0.5 mg. Chronic cilazapril to Pearson. A P value of 0.05 was considered as the 
doses were 2.5, 2.5, 1.0 and 0.5 mg once daily in level of statistical significance. Unless otherwise indi­
groups A, B, C and D, respectively. If necessary, the cated, values are given as means ±  s.d. 
dose was increased once at week 2 to 5.0 mg (groups A,
B), 2.5 mg (group C) or 1.0 mg once daily (group D).
Patient compliance was assessed by capsule counting
and measurements of plasma ACE activity and cilazapri- Results
lat concentrations.
Single dose
Other assessments Patient characteristics are given in Table 1. Phar­
macokinetic data are given in Figure 1 and Table 2. In 
During the single dose part of the study regular contrast to groups A and B, cilazaprilat concentrations 
measurements of plasma concentrations of cilazaprilat declined slower in groups C and D. Accordingly, AUCs
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Table 1 Patient characteristics at baseline
Group
inhibition and cilazaprilat concentrations was +0.8325 
(P< 0.001) at 3 h after drug administration.
A
Patients 
Age (years) 
Male/female 
Body weight (kg)
BP
systolic (mm Hg) 
diastolic (mm Hg)
CLcr (ml min-1) 
Patients with a 
proteinuria of more 
than 1 g day'
7
47 ±10 
6/1 
86 + 8
157 ± 10 
98±4 
130+21 
0
i
B c D
10 5 8
59 + 5 49±9 48 +14
4/6 3/2 3/5
70 + 8 77±10 68 + 6
158 + 11 149 ±3 158±16
97 + 5 98+4 99 + 9
69 + 13 31 ± 6 15+4
2 4 4
BP: blood pressure measured by sphygmomanometer; CLor: 
creatinine clearance; means + s.d. are given.
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Chronic treatment
Cilazaprilat plasma concentrations, ACE inhibition, PRA  
levels Throughout the study cilazaprilat concentrations 
at 24 h were considerably lower in patients from 
groups A and B compared with patients from groups G 
and D (Table 3). Increasing the dose resulted in slightly 
higher cilazaprilat concentrations only in groups CD. 
After week 4 cilazaprilat concentrations measured at 
24 h remained stable. Together with the lower cilazapri­
lat concentrations ACE inhibition at 24 h was essentially 
lower in patients of the high clearance groups. ACE 
inhibition at 3 h after drug administration at week 2 
and 4 was almost complete in all patients. In patients 
treated with the same (‘S’) and those treated with an 
increased (‘1’) dose, comparable levels of ACE inhibition 
were seen at week 11 at 24 h: 62 + 9 and 57+12% in 
the groups AB-S and AB-I (NS), and 85 + 10 and 
90+4% in the groups CD-S and CD-I (NS), respect­
ively. PRA plasma concentrations at baseline were
_1 in group ABi u0.76 + 0.79 and 0.71 + 0.73 nmol 1'
and CD (NS), respectively. In patients treated with the 
same (‘S’) or an increased (‘1’) dose PRA concentrations 
were not significantly different.
Time post dose (h)
Blood pressure and heart rate Changes of mean arterial 
blood pressure are given in Table 3. In patients getting 
the same dose, blood pressure reduction at 24 h 
remained essentially the same throughout the study. 
Increasing the dose at week 2 had no additional effect 
on blood pressure reduction at 24 h in the high clearance 
group (AB-I). In contrast, a slight decline of blood 
pressure after dose increase was observed in the patients 
of the low clearance group (CD-I). Heart rate did not 
essentially change in any group. No significant corre­
lation was found between BP decrease on the one hand 
and baseline MAP, cilazaprilat concentrations, ACE 
inhibition or urinary sodium excretion on the other.
Plasma cilazaprilat concentrations after a single 
dose of 1.0 and 0.5 mg cilazapril (CLcr>40 and <40 ml 
min"1, respectively). Cilazaprilat plasma concentrations of 
patients with an CLcr of less than 40 ml min-1 are 
normalized to a dose of 1 mg. Means + s.e. mean are given. 
-----------CL„. 5-20 ml min“1, n =
Other assessments, adverse events In the low clearance 
groups CD serum creatinine and potassium concen­
trations had risen slightly from 364 + 102 at baseline to
410+138 |j.mol 1 (P
mm n — 5: CL
CLcr > 100 ml min
cr
7.
8;........CL
41-100 ml min-1
cr
n = 10;
21-40 ml
<0.05) at week 11 and from 
4.6 + 0.4 to 5.0+0.4mmol I-1 (P<0.05), respectively. 
Body weight essentially did not change. Proteinuria 
decreased from 3.5+ 2.2 at baseline to 2.0+1.2 gram 
day“ 1 at week 11 (P<0.01) in the 10 patients with a 
proteinuria of more than 1 g day-1. No additional 
were larger in the low creatinine clearance groups. reduction in proteinuria was seen after increasing the 
Average time to peak concentration (fmax) was longer in dose at week 2. Compliance assessed by the percentage 
patients with renal insufficiency. Correlations were found of capsules used as expected for the number of treatment
between CLcr and CL0 (r=  +0.7594, P<0.001), between days was 98 (93-101), 100 (94-102), 100 (99-105) and
CLcr and t (r
1 --------  --- \  /  ^ ± ' ' ' ~ *
0.6474, P <  0.001). (medians and ranges; percentages of more than 100%
CLcr and AUC(0, 24h) (r=  -0.7385, PcO.OOl) and 99 (97-101)% in group A, B, C, and D, respectively
between „ _ _ .
Compared with groups A and B, decreases of ACE were possible since the provided drug bottles had seven
inhibition were seen later in groups C and D (Figure 2). capsules in excess of the expected number of treatment
The correlation coefficient r between the degrees of ACE days). Two patients had short lasting dizziness during
© 1996 Blackwell Science Ltd British Journal of Clinical Pharmacology 42, 615-620
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Table 2 Pharmacokinetic parameters of cilazaprilat after a single oral dose
Group
A B c D ANOVA
Patients 7 10 5 8
CLcr (ml min-1) 130 ±21 69+13 31 ±  6 15 ±  4
AUC(0, 24 h) (ng ml"Mi) 64+13 97 ±27 134± 60 162 ±47 **
Cmax (ng m l- 1 ) 8.8 ±  1.4 12.2 + 3.6 8.7 ±5.0 10.5 ±  3.4 NS
x^nax (h) 2.0 (1-4) 2.5 (1-4) 3.0 (2-8) 6.0 (4-8) **
CL0 (1 h -1) 16.0 ±3.0 11.1 ±3.0 8.7 ±3.7 6.7 ±2.1 **
Unless otherwise indicated results are given as means ±s.d.; ** P <  0.01. Abbreviations: ANOVA: analysis of variance, AUC(0,
24 h): area under the curve, Cmax: peak concentration, tmax: time to peak concentration given as medians (ranges), CL0:
apparent total body clearance. AUC(0, 24 h) and Cmax are normalized to a dose of one mg.
Table 3 Cilazaprilat plasma concentrations (ng ml - 1), baseline supine mean arterial blood pressures (MAP) and their percent
changes during chronic treatment at 3 and 24 h after cilazapril intake in patients getting the same dose at week 2 (‘S’) and in
patients in which dosage was increased at week 2 (‘1’)
Group a
AB-S AB-I CD-S CD-I
Patients 5 12 4 8
CLcr (ml min - 1) 65 ±13 *106 + 34 20 ±11 23 ±8
Cilazapril dose (mg) 2.5 5.0 0.5-1.0 1.0-2.5
Cilazaprilat concentrations
Week 2 (3 h) 50.6 ±15.6 73.6±23.5 25.1 ±7.3 *58.9±38.1
(24 h) 2.0 ±0.6 1.9 ± 0.3 6.7 ±5.8 5.3 ±2.2
Week 4 (3 h) 59.8 ±18.4 68.3 ±29.5 23.8 ±7.0 *60.8 ±25.8
(24 h) 2.3 ±0.6 2.9 ±2.3 5.0 ±2.9 9.3 ±3.7
Week 11 (24 h) 2.4 ±0.8 2.3 ±0.5 5.4±2.7 9.5 ±3.4
Me an arterial pressure
Baseline (mm Hg) 111 ±  10 115 ±  8 107 ±7 118 ±  13
Week 2 (3 h) —17± 8 * —■ 8 ± 6 — 7± 7 — 8 ± 9
(24 h)
+ii * — 3 ± 4 — 11 ±  4 — 1+8
Week 4 (3 h) —17 ±  6 * —7±6 —13 ±5 —  13 ±  11
(24 h) —11 ± 9 *— 1 ±8 — 9 ± 4 — 9 + 8
Week 11 (24 h) OC 1+ OC * _  1 + 7 —12 ± 3 —■ 9 +  11
* P < 0.05 for ÀB-S vs AB-I and CD-S vs CD-I; results are given as means ±s.d
the single dose part. In two patients dry cough was to higher plasma concentrations of 
probably related to the treatment with cilazapril. relatively less binding to ACE and 
elimination. Longer times to peak after lower dosages 
of cilazapril have also been reported in normal volun­
teers [2], In addition, the slower excretion of cilazaprilat 
in the low clearance groups may have contributed to 
the longer times to peak. Theoretically, slower intestinal 
In our patients with normal as well as in those with absorption of cilazapril in the low clearance groups may 
impaired renal function the pharmacokinetic data of the also explain this difference, but studies with other ACE
Discussion
single dose part were comparable with the results inhibitors are not in favour of such 
obtained by others [1, 3, 4]. A strong relationship We can not compare our results 
between creatinine clearance on the one hand and AUC Pillastre et a l  who found a higher Cmax in patients with
hanism [10]. 
the study of
ind clearance of cilazaprilat on the other hand was [3]
observed. Time to peak was longer in patients with patients with a low creatinine clearance. Concentrations 
more severely impaired renal function. The lower dose of cilazaprilat at 96 h were low and the decline of the
concentration was notgiven in the low clearance groups was reason for logarithm of the 
normalization to 1 mg. This may have biased the results linear and showed a wide interindividual variation as 
regarding time to peak, since the higher dose used in reported by others [2, 8], The area from 96 h to infinity
patients higher creatinine clearances may have was approximately half of the total area under the
resulted in a larger amount of drug absorbed, leading curve. Thus, analysis of the total area under the curve
1996 Blackwell Science Ltd British Journal o f  Clinical Pharmacology 42, 615 -620
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Figure 2 Degree of ACE inhibition after a single dose of 1.0 
and 0.5 mg cilazapril (CLcr>40 and <40 ml min-1,
respectively). Means ±s.e. mean are given.
, 5-20 ml min-1.
- i
- C L  
n = 5;
n
m m
CLcr>  100 ml min
CLor 41
n = l.
= 8 ;.........CL
100 ml min-1.
cr 21-40 ml
«  =  10;
response and may be related to the normal course of
chronic renal failure in these patients. However, since
no control groups were included, this remains difficult 
to assess.
In conclusion, chronic treatment with cilazapril was
safe in patients with an CLcr of 8-20 ml min-1 and 
21-40 ml min-1 and a maximal once daily dosage of 
1.0 and 2.5 mg, respectively. No cilazaprilat accumu­
lation was seen. Even at 24 h after drug administration 
cilazaprilat concentrations and degree of ACE inhibition 
in these low clearance groups were high and blood 
pressure response was adequate in most of the patients. 
In contrast, in most patients with an CLcr of more the 
40 ml min ~1 no adequate blood pressure response was 
achieved at once daily dosing.
A critical review of the pharmacokinetic data was kindly 
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